Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

2.

FDA actions against health economic promotions, 2002-2011.

Neumann PJ, Bliss SK.

Value Health. 2012 Sep-Oct;15(6):948-53. doi: 10.1016/j.jval.2012.05.002. Epub 2012 Jun 15.

3.

A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.

Symonds T, Hackford C, Abraham L.

Value Health. 2014 Jun;17(4):433-7. doi: 10.1016/j.jval.2014.03.1718.

4.

An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims.

Chatterjee S, Patel HK, Sansgiry SS.

Pharm Pract (Granada). 2012 Oct;10(4):194-8. Epub 2012 Dec 31.

6.

Evaluating promotional claims as false or misleading.

Brushwood DB, Knox CA, Liu W, Jenkins KA.

Am J Health Syst Pharm. 2013 Nov 1;70(21):1941-4. doi: 10.2146/ajhp130076.

PMID:
24128969
7.

Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.

Kim H.

Int J Health Policy Manag. 2015 Aug 25;4(12):813-21. doi: 10.15171/ijhpm.2015.157.

8.

Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.

Salas M, Martin M, Pisu M, McCall E, Zuluaga A, Glasser SP.

Pharmaceut Med. 2008 Mar 1;22(2). doi: 10.1007/BF03256691.

9.

Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies.

Nguyen D, Seoane-Vazquez E, Rodriguez-Monguio R, Montagne M.

BMC Health Serv Res. 2013 Jan 22;13:27. doi: 10.1186/1472-6963-13-27.

10.

Examining the FDA's oversight of direct-to-consumer advertising.

Gahart MT, Duhamel LM, Dievler A, Price R.

Health Aff (Millwood). 2003 Jan-Jun;Suppl Web Exclusives:W3-120-3.

PMID:
14527243
11.

Content analysis of false and misleading claims in television advertising for prescription and nonprescription drugs.

Faerber AE, Kreling DH.

J Gen Intern Med. 2014 Jan;29(1):110-8. doi: 10.1007/s11606-013-2604-0.

12.

The regulation of patient-reported outcome claims: need for a flexible standard.

Morris LA, Miller DW.

Value Health. 2002 Jul-Aug;5(4):372-81. Review.

13.

Regulation of prescription drug promotion: direct-to-consumer advertising.

Baylor-Henry M, Drezin NA.

Clin Ther. 1998;20 Suppl C:C86-95. Review.

PMID:
9915094
14.

Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.

Kannan S, Gowri S, Tyagi V, Kohli S, Jain R, Kapil P, Bhardwaj A.

Int J Risk Saf Med. 2015;27(2):77-83. doi: 10.3233/JRS-150644.

PMID:
26410010
15.

When Does FDAMA Section 114 Apply? Ten Case Studies.

Neumann PJ, Saret CJ.

Value Health. 2015 Jul;18(5):682-9. doi: 10.1016/j.jval.2015.02.013. Epub 2015 Apr 16.

17.
20.

Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation.

Zetterqvist AV, Merlo J, Mulinari S.

PLoS Med. 2015 Feb 17;12(2):e1001785. doi: 10.1371/journal.pmed.1001785. eCollection 2015 Feb.

Supplemental Content

Support Center